Description
The Apple Watch (AW) irregular rhythm notification (IRN) feature uses photoplethysmography to identify prolonged episodes of irregular rhythm suggestive of atrial fibrillation (AF). IRN is FDA cleared for those with no previous history of AF, however, these devices are increasingly being used for AF management. The objective of the present study was to determine the accuracy of the IRN in subjects with a previous diagnosis of nonpermanent AF. In a population with known AF, the AW IRN had a low rate of false positive detections and high specificity. Sensitivity for detection by subject and by AF episode was lower. The current IRN algorithm appears accurate for AF screening as currently cleared, but increased sensitivity and wear times would be necessary for disease management.
Learning Objectives
- Determine the accuracy of the irregular rhythm notification with an Apple Watch in patients with a previous diagnosis of nonpermanent atrial fibrillation.
Article Authors and Podcast Contributors
Article Authors
Jeremiah Wasserlauf, MD, MS, Kelly Vogel, BS, Cailin Whisler, MPH, Emelia Benjamin, MD, ScM, Robert Helm, MD, Daniel A. Steinhaus, MD, Omair Yousuf, MD, Rod S. Passman MD, MSCE
Podcast Contributors
Deepthy Varghese, MSN, ACNP, FNP of Northside Hospital
Martha G. Ferrara, DNP, FNP, FHRS, CCDS, of White Plains Hospital
Dinesh Sharma, MD, MPH, FHRS, of Naples Heart Institute
Disclosures
All relevant financial relationships have been mitigated.Host Disclosure(s):
D. Varghese: No relevant financial relationships with ineligible companies to disclose.
Contributor Disclosure(s):
M. Ferrara: Honoraria/Speaking/Consulting Fee: Boston Scientific, Rhythm Management Group Corporation, Travel (Other Activities): Medtronic
D. Sharma: No relevant financial relationships with ineligible companies to disclose.
Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose.
S. Sailor: No relevant financial relationships with ineligible companies to disclose.